Clinical Research Directory
Browse clinical research sites, groups, and studies.
OPT-CAD Score GUIded Dual ANtiplatelet De-esCalation Time
Sponsor: Shenyang Northern Hospital
Summary
Monotherapy with a P2Y12 inhibitor after a minimum period of DAPT following percutaneous coronary intervention (PCI) is an emerging de-escalation antiplatelet strategy in recent years. However, the optimal timing for de-escalating DAPT in ACS patients undergoing PCI remains debated. The OPT-CAD score is a risk stratification tool derived from Chinese patients which has been demonstrated superior predictive capabilities for ischemic events and all-cause mortality than the GRACE score. Therefore, we hypothesize that the OPT-CAD score can be used to guide the timing of the DAPT de-escalation strategy to monotherapy with P2Y12 inhibitors for ACS patients, that is, low-risk patients could be de-escalated after 1 month, while high-risk patients could be de-escalated after 3 months, so as to achieve individualized antithrombotic therapy and maximize patient benefit.
Official title: OPT-CAD Score Guided Dual Antiplatelet De-escalation Time in Patients With Acute Coronary Syndrome Undergoing Undergoing Percutaneous Coronary Intervention: a Register-based Randomized Controlled Study
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
3490
Start Date
2024-07-02
Completion Date
2027-12-31
Last Updated
2025-09-10
Healthy Volunteers
No
Conditions
Interventions
standard DAPT
standard DAPT with aspirin and a P2Y12 inhibitor for 12 months after DES implantation.
OPT-CAD score guided DAPT de-escalation
De-escalation DAPT at 3 months for moderate to high risk patients and de-escalation DAPT at 1 month for low risk patients.
Locations (1)
General Hospital of Northern Theater Command
Shenyang, Liaoning, China